APA (7th ed.) Citation

Markman, B., Day, D., Park, J., Coward, J., Bishnoi, S., Kotasek, D., . . . Tse, A. (2020). 1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing. Annals of Oncology, 31, S722. https://doi.org/10.1016/j.annonc.2020.08.1177

Chicago Style (17th ed.) Citation

Markman, B., et al. "1057P Preliminary Pharmacokinetics (PK), Safety and Efficacy of Two Dosing Regimens of CS1003 (anti-PD-1) in Solid Tumours: 200 Mg Every 3-week (Q3W) and 400 Mg Every 6-week (Q6W) Dosing." Annals of Oncology 31 (2020): S722. https://doi.org/10.1016/j.annonc.2020.08.1177.

MLA (9th ed.) Citation

Markman, B., et al. "1057P Preliminary Pharmacokinetics (PK), Safety and Efficacy of Two Dosing Regimens of CS1003 (anti-PD-1) in Solid Tumours: 200 Mg Every 3-week (Q3W) and 400 Mg Every 6-week (Q6W) Dosing." Annals of Oncology, vol. 31, 2020, p. S722, https://doi.org/10.1016/j.annonc.2020.08.1177.